ArticleNeurochemical research2025
Target Identification of Ginsenosides Against Cognitive Impairment by Using Mass Spectrometry-Based Cellular Thermal Shift Assay (CETSA).
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenosides, the primary bioactive constituents of ginseng, are recognized for its potential to mitigate cognitive deficits associated with neurodegenerative conditions. Nevertheless, its molecular targets within cerebral tissues remain to be elucidated. First, cellular thermal shift assay (CETSA) combined with liquid chromatography mass spectrometry (LC-MS) was used to identify potential proteins of ginsenosides intersecting in the disease databases. Secondly, biolayer interferometry (BLI) was used to detect and verify the strongest binding compounds and to predict binding sites through molecular docking. Next, the functional characteristics and molecular properties of these candidate proteins were analyzed by bioinformatics. Finally, the mRNA expression levels of candidate genes in murine hippocampus were quantified via qRT-PCR following PPD treatment. Integration of CETSA proteomic data with the disease database identified three overlapping gens. BLI analysis and molecular docking showed that compound K (CK) and ginsenoside Rh2 were well combined with postsynaptic density protein 95 (PSD95). CK and PPD work well with ATXN10. PPD, Rh2 and ANXA2 are well combined. Bioinformatics analysis suggested that the target genes were significantly enriched in AMPA glutamate receptors. qRT-PCR analysis revealed that PPD administration modulated the mRNA expression of synaptic proteins, including PSD95, ANXA2, and the AMPA receptor subunit GluA1, in murine hippocampal tissue. These results suggest that PSD95, ANXA2 and ATXN10 are potential brain targets of ginsenosides in cognitive impairment. PPD has a good effect on the mRNA expression of PSD95, ANXA2 and GluA1 in the brain of mice with cognitive impairment.
Indexed as
Identifiers
40323441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.